A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Melanoma|Ovarian Cancer|Sarcoma|Non-small Cell Lung Cancer|Breast Cancer
Interventions: BIOLOGICAL: IDC-G305
Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)